特利加压素治疗肝肾综合征:CONFIRM试验如何推动进展
肝肾综合征是晚期肝硬化患者发生的急性肾损伤,病死率高,美国尚无获批药物。CONFIRM试验显示特利加压素组HRS逆转率更高,但呼吸不良事件增加且无死亡率获益,未获FDA批准。本文回顾审批历史并探讨其未来定位。
要点
- 特利加压素可提高HRS逆转率,但未显示死亡率获益。
- 呼吸不良事件增加是FDA未批准的主要担忧之一。
- 美国尚无获批的HRS治疗药物,欧洲多用特利加压素。
核心结论
- CONFIRM试验达到主要终点,特利加压素组HRS逆转率更高,但因呼吸不良事件增加且无死亡率获益,未获FDA批准。
研究设计与样本
- CONFIRM为多中心、随机、安慰剂对照、双盲研究,评估特利加压素治疗1型肝肾综合征的疗效与安全性,是北美第三个相关随机试验。
主要发现
- 特利加压素组HRS逆转率高于安慰剂组,达到主要终点。
- 观察到呼吸不良事件发生率增加,且缺乏死亡率获益证据。
临床怎么用
- 在美国尚无获批药物背景下,特利加压素的使用需权衡HRS逆转获益与呼吸不良事件风险。
- 欧洲等多国将特利加压素作为HRS一线治疗。
局限性
- CONFIRM试验存在呼吸不良事件增加及缺乏死亡率获益证据的问题,导致未获FDA批准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hepatorenal syndrome (HRS) is a form of acute kidney injury (AKI) occurring in patients with advanced cirrhosis and is associated with significant morbidity and mortality. The pathophysiology underlying HRS begins with increasing portal pressures leading to the release of vasodilatory substances that result in pooling blood in the splanchnic system and a corresponding reduction in effective circulating volume. Compensatory activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system and release of arginine vasopressin serve to defend mean arterial pressure but at the cost of severe constriction of the renal vasculature, leading to a progressive, often fulminant form of AKI. There are no approved treatments for HRS in the United States, but multiple countries, including much of Europe, use terlipressin, a synthetic vasopressin analogue, as a first-line therapy. CONFIRM (A Multi-Center, Randomized, Placebo Controlled, Double-Blind Study to Confirm Efficacy and Safety of Terlipressin in Subjects With Hepatorenal Syndrome Type 1), the third randomized trial based in North America evaluating terlipressin, met its primary end point of showing greater rates of HRS reversal in the terlipressin arm. However, due to concerns about the apparent increased rates of respiratory adverse events and a lack of evidence for mortality benefit, terlipressin was not approved by the Food and Drug Administration (FDA). We explore the history of regulatory approval for terlipressin in the United States, examine the results from CONFIRM and the concerns they raised, and consider the future role of terlipressin in this critical clinical area of continued unmet need.
引用
- Belcher JM, Parada XV, Simonetto DA, et al. Terlipressin and the Treatment of Hepatorenal Syndrome: How the CONFIRM Trial Moves the Story Forward. Am J Kidney Dis. 2021. PMID: 34606933. doi:10.1053/j.ajkd.2021.08.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。